You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Validating the MicroKine Assay for Use in Identifying Personalized Precision Therapies for Pediatric SepsisSBC: PreDxion Bio, Inc. Topic: NICHD
Project Summary Abstract PreDxion BioLLC is a precision medicine diagnostic company developing an assay platformthe MicroKineassay cartridge and readerthat measures serum proteins in less thanminutes from a single drop of bloodThis fastactionable information allows for the first time individualized precision medicine aimed at reducing pediatric morbidity and mortality in pediatric sepsisthe number ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: ONL Therapeutics, Inc. Topic: NEI
PROJECT SUMMARYABSTRACT Age related macular degenerationAMDis the leadingand due to the aging baby boomersa growing cause of irreversible vision loss in the United Statesand is strongly associated with exposure to cigarette smokeCSand high fat dietsHFDWhile effective treatment is available for neovascular AMDthe AREDS II antioxidant vitamins are the only proven treatment for intermediate dry AMDUn ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
The Novel Biopsy Needle Design and Delivery System to Minimize Needle Deflection and Optimize Needle Positioning to Improve Lesion Sampling Accuracy Using a Co-registered MRI/US Fusion Biopsy PlatformSBC: ProDevice Medical Supplies and Equipment LLC Topic: 101
Project Abstract Accurate diagnosis of prostate cancer is essential for individualized treatment decisionsWith more recent advances in multiparametric magnetic resonance imagingmpMRIsuspicious cancer lesions can be identifiedCo registered MRI ultrasound fusion targeted biopsyMRF TBallows the sampling of specific lesions of concern within the prostate has emerged as the preferred diagnostic procedu ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
The Microscopic Imaging of Epigenetic Landscape- NeuroDevelopment (MIEL-ND) assay: a high throughput platform to screen compounds for neurodevelopmental effectsSBC: VALA SCIENCES, INC. Topic: 101
Neurodevelopmental diseasesNDDsAutism Spectrum DisorderASDIntellectual DisabilitiesBipolar disordersand Schizophreniaetcare prevalent and due to errors in neurodifferentiation and neurocircuitryWhile NDDsin many casesare due to inherited mutationsevidence is mounting that prenatal exposure to environmental toxicants also cause NDDs via disruption of epigeneticse gmodifications of histoneshistone t ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: DYNAVAX TECHNOLOGIES CORPORATION Topic: NIDDK
DESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation is unable to meet the needs of all patients afflicted with HF. We have shown that chronic liver injury involves the activation of Toll-like receptor 7 (TLR7) and TLR9. We further demonstrated that the ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: SIXONE SOLUTIONS, LLC Topic: NCI
DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: BRILLIANT BIOSCIENCES INC. Topic: NIA
One in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Odyssey Science Innovations, LLC Topic: NIDA
DESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
SBC: Myolex Inc Topic: NIAMS
PROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Lacerta Therapeutics, Inc. Topic: 102
Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health